Written questions by Perteghella.

What steps he is taking to ensure timely patient access to innovative treatments for rare cancers, including neuroendocrine cancers.

Improving the early diagnosis of rare cancers, including neuroendocrine cancers, is a priority for the Government. In February, the Government published the first ever National Cancer Plan with a dedicated chapter on rare cancers.The Government is committed to transforming diagnostic services and will support the National Health Service to increase capacity to meet the demand for diagnostic services through investment in new capacity, including magnetic resonance imaging (MRI) and computed tomography (CT) scanners.Neuroendocrine cancers benefit from system‑wide early diagnosis initiatives, including non‑specific symptoms pathways, and expanded diagnostic capacity through community diagnostic centres. NHS England has rolled out non‑specific symptom pathways nationally, designed to support patients whose symptoms do not clearly align with a single urgent cancer referral route, which particularly benefits rarer cancers such as neuroendocrine cancers.NHS England recognises that cross sectional imaging, such as CT and/or MRI scanning in particular, play a crucial role in the diagnosis of neuroendocrine cancers. Whilst there is still more work to do, NHS England continues to prioritise and support access to CT/MRI scanning services through targeted capital investment which over the last five years has contributed to a 37% increase in CT scanners and a 33% increase in MRI scanners across the country.In addition to imaging, the diagnosis of neuroendocrine cancer relies on a combination of biochemical tests, including blood and urine markers, and histopathological confirmation, typically obtained via biopsy. As part of broader efforts to strengthen diagnostic services, NHS England is investing in histopathology modernisation, including automation and digital pathology, to support improvements in diagnostic accuracy, timeliness, and equitable access to high-quality care.The National Institute of Health and Care Excellence's (NICE’s) guideline makes recommendations by site of the suspected cancer that clinicians should use to guide referral for specialist opinion.We will increase access to the best innovative cancer treatments for all. The Cancer Drugs Fund has helped to ensure that, according to industry data, patients in England receive new cancer treatments 50% faster than the European Union average, and it will continue to provide earlier access to promising new treatments. By April 2026, a joint process between NICE and the Medicines and Healthcare products Regulatory Agency will boost the speed of decisions on the licensing and appraisal of medicines, so that recommendations for the NHS to fund new drugs can be made faster.Patients with rare cancers will benefit from a move to specialist, multi-disciplinary teams, that cover multiple healthcare providers. This will allow them to benefit from the input of specialist centres and access to the best evidence-based care. The Department is exploring novel procurement routes for diagnostics and treatments for rare cancers, such as advanced market commitments, to stimulate innovation in cancer treatments.Where appropriate, every person diagnosed with cancer will have access to personalised care, including needs assessment, a care plan, and health and wellbeing information and support. This includes provision of information, empowering people to manage their care and the impact of their cancer. Personalised care ensures that each person’s care is planned holistically, covering mental and physical health as well as any practical or financial concerns. NHS England is committed to ensuring that all cancer patients get access to these interventions ensuring care is focused on what matters most to each person.Cancer Alliances play a key role in transforming care and support for patients, working closely with the wider health and care system.

What assessment he has made of the adequacy of patient access to specialist treatments for neuroendocrine cancer, including peptide receptor radionuclide therapy.

Improving the early diagnosis of rare cancers, including neuroendocrine cancers, is a priority for the Government. In February, the Government published the first ever National Cancer Plan with a dedicated chapter on rare cancers.The Government is committed to transforming diagnostic services and will support the National Health Service to increase capacity to meet the demand for diagnostic services through investment in new capacity, including magnetic resonance imaging (MRI) and computed tomography (CT) scanners.Neuroendocrine cancers benefit from system‑wide early diagnosis initiatives, including non‑specific symptoms pathways, and expanded diagnostic capacity through community diagnostic centres. NHS England has rolled out non‑specific symptom pathways nationally, designed to support patients whose symptoms do not clearly align with a single urgent cancer referral route, which particularly benefits rarer cancers such as neuroendocrine cancers.NHS England recognises that cross sectional imaging, such as CT and/or MRI scanning in particular, play a crucial role in the diagnosis of neuroendocrine cancers. Whilst there is still more work to do, NHS England continues to prioritise and support access to CT/MRI scanning services through targeted capital investment which over the last five years has contributed to a 37% increase in CT scanners and a 33% increase in MRI scanners across the country.In addition to imaging, the diagnosis of neuroendocrine cancer relies on a combination of biochemical tests, including blood and urine markers, and histopathological confirmation, typically obtained via biopsy. As part of broader efforts to strengthen diagnostic services, NHS England is investing in histopathology modernisation, including automation and digital pathology, to support improvements in diagnostic accuracy, timeliness, and equitable access to high-quality care.The National Institute of Health and Care Excellence's (NICE’s) guideline makes recommendations by site of the suspected cancer that clinicians should use to guide referral for specialist opinion.We will increase access to the best innovative cancer treatments for all. The Cancer Drugs Fund has helped to ensure that, according to industry data, patients in England receive new cancer treatments 50% faster than the European Union average, and it will continue to provide earlier access to promising new treatments. By April 2026, a joint process between NICE and the Medicines and Healthcare products Regulatory Agency will boost the speed of decisions on the licensing and appraisal of medicines, so that recommendations for the NHS to fund new drugs can be made faster.Patients with rare cancers will benefit from a move to specialist, multi-disciplinary teams, that cover multiple healthcare providers. This will allow them to benefit from the input of specialist centres and access to the best evidence-based care. The Department is exploring novel procurement routes for diagnostics and treatments for rare cancers, such as advanced market commitments, to stimulate innovation in cancer treatments.Where appropriate, every person diagnosed with cancer will have access to personalised care, including needs assessment, a care plan, and health and wellbeing information and support. This includes provision of information, empowering people to manage their care and the impact of their cancer. Personalised care ensures that each person’s care is planned holistically, covering mental and physical health as well as any practical or financial concerns. NHS England is committed to ensuring that all cancer patients get access to these interventions ensuring care is focused on what matters most to each person.Cancer Alliances play a key role in transforming care and support for patients, working closely with the wider health and care system.

Whether neuroendocrine cancers are included in NHS England’s wider early cancer diagnosis initiatives, including the Faster Diagnosis Standard.

Improving the early diagnosis of rare cancers, including neuroendocrine cancers, is a priority for the Government. In February, the Government published the first ever National Cancer Plan with a dedicated chapter on rare cancers.The Government is committed to transforming diagnostic services and will support the National Health Service to increase capacity to meet the demand for diagnostic services through investment in new capacity, including magnetic resonance imaging (MRI) and computed tomography (CT) scanners.Neuroendocrine cancers benefit from system‑wide early diagnosis initiatives, including non‑specific symptoms pathways, and expanded diagnostic capacity through community diagnostic centres. NHS England has rolled out non‑specific symptom pathways nationally, designed to support patients whose symptoms do not clearly align with a single urgent cancer referral route, which particularly benefits rarer cancers such as neuroendocrine cancers.NHS England recognises that cross sectional imaging, such as CT and/or MRI scanning in particular, play a crucial role in the diagnosis of neuroendocrine cancers. Whilst there is still more work to do, NHS England continues to prioritise and support access to CT/MRI scanning services through targeted capital investment which over the last five years has contributed to a 37% increase in CT scanners and a 33% increase in MRI scanners across the country.In addition to imaging, the diagnosis of neuroendocrine cancer relies on a combination of biochemical tests, including blood and urine markers, and histopathological confirmation, typically obtained via biopsy. As part of broader efforts to strengthen diagnostic services, NHS England is investing in histopathology modernisation, including automation and digital pathology, to support improvements in diagnostic accuracy, timeliness, and equitable access to high-quality care.The National Institute of Health and Care Excellence's (NICE’s) guideline makes recommendations by site of the suspected cancer that clinicians should use to guide referral for specialist opinion.We will increase access to the best innovative cancer treatments for all. The Cancer Drugs Fund has helped to ensure that, according to industry data, patients in England receive new cancer treatments 50% faster than the European Union average, and it will continue to provide earlier access to promising new treatments. By April 2026, a joint process between NICE and the Medicines and Healthcare products Regulatory Agency will boost the speed of decisions on the licensing and appraisal of medicines, so that recommendations for the NHS to fund new drugs can be made faster.Patients with rare cancers will benefit from a move to specialist, multi-disciplinary teams, that cover multiple healthcare providers. This will allow them to benefit from the input of specialist centres and access to the best evidence-based care. The Department is exploring novel procurement routes for diagnostics and treatments for rare cancers, such as advanced market commitments, to stimulate innovation in cancer treatments.Where appropriate, every person diagnosed with cancer will have access to personalised care, including needs assessment, a care plan, and health and wellbeing information and support. This includes provision of information, empowering people to manage their care and the impact of their cancer. Personalised care ensures that each person’s care is planned holistically, covering mental and physical health as well as any practical or financial concerns. NHS England is committed to ensuring that all cancer patients get access to these interventions ensuring care is focused on what matters most to each person.Cancer Alliances play a key role in transforming care and support for patients, working closely with the wider health and care system.

What steps he is taking to improve the early diagnosis of neuroendocrine cancers.

Improving the early diagnosis of rare cancers, including neuroendocrine cancers, is a priority for the Government. In February, the Government published the first ever National Cancer Plan with a dedicated chapter on rare cancers.The Government is committed to transforming diagnostic services and will support the National Health Service to increase capacity to meet the demand for diagnostic services through investment in new capacity, including magnetic resonance imaging (MRI) and computed tomography (CT) scanners.Neuroendocrine cancers benefit from system‑wide early diagnosis initiatives, including non‑specific symptoms pathways, and expanded diagnostic capacity through community diagnostic centres. NHS England has rolled out non‑specific symptom pathways nationally, designed to support patients whose symptoms do not clearly align with a single urgent cancer referral route, which particularly benefits rarer cancers such as neuroendocrine cancers.NHS England recognises that cross sectional imaging, such as CT and/or MRI scanning in particular, play a crucial role in the diagnosis of neuroendocrine cancers. Whilst there is still more work to do, NHS England continues to prioritise and support access to CT/MRI scanning services through targeted capital investment which over the last five years has contributed to a 37% increase in CT scanners and a 33% increase in MRI scanners across the country.In addition to imaging, the diagnosis of neuroendocrine cancer relies on a combination of biochemical tests, including blood and urine markers, and histopathological confirmation, typically obtained via biopsy. As part of broader efforts to strengthen diagnostic services, NHS England is investing in histopathology modernisation, including automation and digital pathology, to support improvements in diagnostic accuracy, timeliness, and equitable access to high-quality care.The National Institute of Health and Care Excellence's (NICE’s) guideline makes recommendations by site of the suspected cancer that clinicians should use to guide referral for specialist opinion.We will increase access to the best innovative cancer treatments for all. The Cancer Drugs Fund has helped to ensure that, according to industry data, patients in England receive new cancer treatments 50% faster than the European Union average, and it will continue to provide earlier access to promising new treatments. By April 2026, a joint process between NICE and the Medicines and Healthcare products Regulatory Agency will boost the speed of decisions on the licensing and appraisal of medicines, so that recommendations for the NHS to fund new drugs can be made faster.Patients with rare cancers will benefit from a move to specialist, multi-disciplinary teams, that cover multiple healthcare providers. This will allow them to benefit from the input of specialist centres and access to the best evidence-based care. The Department is exploring novel procurement routes for diagnostics and treatments for rare cancers, such as advanced market commitments, to stimulate innovation in cancer treatments.Where appropriate, every person diagnosed with cancer will have access to personalised care, including needs assessment, a care plan, and health and wellbeing information and support. This includes provision of information, empowering people to manage their care and the impact of their cancer. Personalised care ensures that each person’s care is planned holistically, covering mental and physical health as well as any practical or financial concerns. NHS England is committed to ensuring that all cancer patients get access to these interventions ensuring care is focused on what matters most to each person.Cancer Alliances play a key role in transforming care and support for patients, working closely with the wider health and care system.

What guidance is issued to GPs on recognising symptoms of neuroendocrine cancers.

Improving the early diagnosis of rare cancers, including neuroendocrine cancers, is a priority for the Government. In February, the Government published the first ever National Cancer Plan with a dedicated chapter on rare cancers.The Government is committed to transforming diagnostic services and will support the National Health Service to increase capacity to meet the demand for diagnostic services through investment in new capacity, including magnetic resonance imaging (MRI) and computed tomography (CT) scanners.Neuroendocrine cancers benefit from system‑wide early diagnosis initiatives, including non‑specific symptoms pathways, and expanded diagnostic capacity through community diagnostic centres. NHS England has rolled out non‑specific symptom pathways nationally, designed to support patients whose symptoms do not clearly align with a single urgent cancer referral route, which particularly benefits rarer cancers such as neuroendocrine cancers.NHS England recognises that cross sectional imaging, such as CT and/or MRI scanning in particular, play a crucial role in the diagnosis of neuroendocrine cancers. Whilst there is still more work to do, NHS England continues to prioritise and support access to CT/MRI scanning services through targeted capital investment which over the last five years has contributed to a 37% increase in CT scanners and a 33% increase in MRI scanners across the country.In addition to imaging, the diagnosis of neuroendocrine cancer relies on a combination of biochemical tests, including blood and urine markers, and histopathological confirmation, typically obtained via biopsy. As part of broader efforts to strengthen diagnostic services, NHS England is investing in histopathology modernisation, including automation and digital pathology, to support improvements in diagnostic accuracy, timeliness, and equitable access to high-quality care.The National Institute of Health and Care Excellence's (NICE’s) guideline makes recommendations by site of the suspected cancer that clinicians should use to guide referral for specialist opinion.We will increase access to the best innovative cancer treatments for all. The Cancer Drugs Fund has helped to ensure that, according to industry data, patients in England receive new cancer treatments 50% faster than the European Union average, and it will continue to provide earlier access to promising new treatments. By April 2026, a joint process between NICE and the Medicines and Healthcare products Regulatory Agency will boost the speed of decisions on the licensing and appraisal of medicines, so that recommendations for the NHS to fund new drugs can be made faster.Patients with rare cancers will benefit from a move to specialist, multi-disciplinary teams, that cover multiple healthcare providers. This will allow them to benefit from the input of specialist centres and access to the best evidence-based care. The Department is exploring novel procurement routes for diagnostics and treatments for rare cancers, such as advanced market commitments, to stimulate innovation in cancer treatments.Where appropriate, every person diagnosed with cancer will have access to personalised care, including needs assessment, a care plan, and health and wellbeing information and support. This includes provision of information, empowering people to manage their care and the impact of their cancer. Personalised care ensures that each person’s care is planned holistically, covering mental and physical health as well as any practical or financial concerns. NHS England is committed to ensuring that all cancer patients get access to these interventions ensuring care is focused on what matters most to each person.Cancer Alliances play a key role in transforming care and support for patients, working closely with the wider health and care system.

What consideration his Department has given to the potential role of a respiratory Modern Service Framework in reducing winter pressures on the NHS by improving outcomes for long-term respiratory conditions and short-term respiratory illnesses such as flu.

Modern service frameworks will define an aspirational, long-term outcome goal for a major condition and will then identify the best evidenced interventions and the support for delivery. Early priorities will include cardiovascular disease, severe mental illness, and the first ever service framework for frailty and dementia.The Government will consider other long-term conditions for future waves of modern service frameworks, including respiratory conditions. The criteria for determining other conditions for future modern service frameworks will be based on where there is potential for rapid and significant improvements in quality of care and productivity. There has not, therefore, been a specific assessment made in relation to winter pressures.NHS England, working with the Department, the UK Health Security Agency, and other partners, took action to reduce the impact of respiratory conditions on the National Health Service during the winter of 2025/26. Further details of the actions taken to reduce demand on acute services during winter is available at the following link:https://www.england.nhs.uk/long-read/urgent-and-emergency-care-plan-2025-26/

What assessment his Department has made of the number of emergency hospital admissions for respiratory conditions in (a) South Warwickshire, (b) the West Midlands region, and (c) England.

NHS England routinely collects data on emergency admissions, including the chief complaint recorded at attendance.In February 2026, there were 273,367 emergency admitted attendances in England, 14.9% of which recorded airway or breathing-related conditions as the chief complaint.In the West Midlands, there were 57,805 emergency admitted attendances, with 15.8% relating to airway or breathing‑related conditions.At the South Warwickshire NHS Foundation Trust, there were 2,025 emergency admitted attendances, 12.8% of which were for airway or breathing‑related conditions as the chief complaint.

Whether his Department plans to introduce a national standard for providing (a) full and (b) timely responses to complaints made within healthcare settings across England.

The Local Authority Social Services and National Health Service Complaints (England) Regulations 2009 set out in law the minimum standards National Health Service organisations must adhere to in respect of their complaint handling arrangements. This includes the need to investigate complaints speedily and efficiently and keep the complainant informed during the investigation. The response must include, amongst other things, an explanation of how the complaint has been considered and the conclusions reached.We have committed in the 10-Year Health Plan to reform the NHS complaints process and set clear standards for both the timeliness and the quality of responses to complaints. We expect this to be within the portfolio of the new National Director for Patient Experience, for which recruitment will soon be underway.

What consideration he has given to amending the NHS Charges to Overseas Visitors Regulations 2015 to remove the exclusion of assisted conception services for Ukrainian nationals who are lawfully resident in the UK under (a) the Homes for Ukraine and (b) Ukraine Permission to Extend visa schemes.

Assisted conception services often require long-term treatment, lasting months or years, which does not align with the short-term nature of all visas that are covered by the Immigration Health Surcharge, including the Homes for Ukraine and Ukraine Permission Extension Schemes. There are currently no plans to amend the NHS (Charges to Overseas Visitors) Regulations 2015.

For what reason assisted conception services are excluded from the exemption from NHS charges for people in the UK under (a) the Homes for Ukraine and (b) Ukraine Permission to Extend visa schemes.

Assisted conception services often require long-term treatment, lasting months or years, which does not align with the short-term nature of all visas that are covered by the Immigration Health Surcharge, including the Homes for Ukraine and Ukraine Permission Extension Schemes. There are currently no plans to amend the NHS (Charges to Overseas Visitors) Regulations 2015.

What steps he is taking to help tackle the harm caused by sodium valproate to people in (a) England, (b) Warwickshire, and (c) Stratford-on-Avon.

Everyone who has been harmed from sodium valproate has our deepest sympathies.The Independent Medicines and Medical Devices Safety Review, First Do No Harm, identified significant shortcomings in National Health Service care pathways for people harmed by sodium valproate, including fragmented services, limited diagnostic expertise, delays in diagnosis, and inequitable access to multidisciplinary care.In response, NHS England has commissioned a Fetal Exposure to Medicines Services Pilot, being delivered by the NHS in Newcastle and Manchester. The pilot provides multidisciplinary diagnostic assessment and is informing the development of improved care pathways, better coordination of care, and reduced reliance on emergency care. Findings from the pilot will inform future decisions on the commissioning of services, subject to funding.The Government is also carefully considering the Patient Safety Commissioner’s recommendations made in the Hughes Report, which includes proposed approaches to redress for those harmed by sodium valproate. I recently met the Patient Safety Commissioner to provide an update on the ongoing health initiatives led by the Department regarding sodium valproate and pelvic mesh, and agreed to providing an update on her report recommendations in due course.

What assessment his Department has made of how NHS services support people with coeliac disease who are facing financial difficulties.

We recognise the pressures people are facing with the rising cost of living and the increased costs incurred by people with coeliac disease because they have to buy gluten-free options, which are often more expensive than their non-gluten-free equivalents.The Department carried out an analysis of this issue as part of its Equalities Impact Assessment which was published as part of the consultation on the Availability of gluten-free foods on prescription in primary care. A copy of the assessment following this consultation is available at the following link:https://www.gov.uk/government/consultations/availability-of-gluten-free-foods-on-nhs-prescriptionWe looked at the equality impact assessment and the consultation responses and, as a result, made the decision to retain gluten-free bread and mixes on National Health Service prescription. This will help enable people with coeliac disease to obtain their basic food needs and mitigate the risk that those on lower incomes are not able to purchase their own gluten-free foods from retail outlets.The national prescribing position in England remains that gluten-free bread and mixes can be provided to all eligible coeliac patients on an NHS prescription, and a wide range of these items continue to be listed in Part XV of the Drug Tariff. This means that prescribers can issue NHS prescriptions, based on a shared decision between prescriber and patient, while also being mindful of local and national guidance.

How many neurologists working in the NHS have specialist training in Parkinson’s disease in (a) England and (b) Coventry and Warwickshire.

The Department does not hold a central count of the number of specialist Parkinson’s nurses employed across the National Health Service, either in England as a whole or in Coventry and Warwickshire specifically.Specialist Parkinson’s nurses play a vital role in supporting people with Parkinson’s disease through personalised care, medicines management, and advice on self‑management. However, these posts are not recorded as a discrete workforce category in national workforce datasets. Workforce planning, including decisions about the number and type of specialist nurses needed locally, is the responsibility of individual employers and their integrated care boards (ICBs), which are best placed to assess the needs of their populations.The Department does not hold data on the number of neurologists with specialist training in Parkinson’s disease, either nationally in England or within Coventry and Warwickshire. National workforce datasets do not record condition‑specific sub‑specialisms within neurology, and responsibility for determining local specialist workforce configurations rests with individual employers and ICBs.As of October 2025, there are 51 full-time equivalent (FTE) doctors working in the specialty of neurology within the Coventry and Warwickshire ICB area. This is a decrease of one, or 2.2%, compared to last year and an increase of 23, or 79.3%, compared to five years ago. This includes 21 FTE consultants. This is an increase of two, or 9.9%, compared to last year and six, or 41.5%, compared to five years ago.

How many specialist Parkinson’s nurses are currently employed within the NHS in (a) England and (b) Coventry and Warwickshire.

The Department does not hold a central count of the number of specialist Parkinson’s nurses employed across the National Health Service, either in England as a whole or in Coventry and Warwickshire specifically.Specialist Parkinson’s nurses play a vital role in supporting people with Parkinson’s disease through personalised care, medicines management, and advice on self‑management. However, these posts are not recorded as a discrete workforce category in national workforce datasets. Workforce planning, including decisions about the number and type of specialist nurses needed locally, is the responsibility of individual employers and their integrated care boards (ICBs), which are best placed to assess the needs of their populations.The Department does not hold data on the number of neurologists with specialist training in Parkinson’s disease, either nationally in England or within Coventry and Warwickshire. National workforce datasets do not record condition‑specific sub‑specialisms within neurology, and responsibility for determining local specialist workforce configurations rests with individual employers and ICBs.As of October 2025, there are 51 full-time equivalent (FTE) doctors working in the specialty of neurology within the Coventry and Warwickshire ICB area. This is a decrease of one, or 2.2%, compared to last year and an increase of 23, or 79.3%, compared to five years ago. This includes 21 FTE consultants. This is an increase of two, or 9.9%, compared to last year and six, or 41.5%, compared to five years ago.

If he will undertake a review of the effectiveness of the Vaccine Damage Payment Scheme.

Our deepest sympathies are with those who have experienced harm following vaccination and with their families. Ministers recognise that concerns have been raised with the Vaccine Damage Payment Scheme (VDPS) and continue to consider potential reforms to the scheme.In parallel, the Department has been working with the NHS Business Services Authority (NHS BSA), the administrators of the VDPS, to process claims at a faster rate. The time it takes to process a claim depends on the complexity of the case and the length of time healthcare providers take to supply the requested medical records. The NHS BSA is engaging with healthcare providers to improve the return rate of these records, which is essential to assessing claims, including though submitting subject access requests.Information on COVID-19 claims to the VDPS is published on a quarterly basis by the NHS BSA. Further information is available at the following link:https://opendata.nhsbsa.net/dataset/vdps-covid-19

What recent assessment he has made of trends in the processing time for claims made under the Vaccine Damage Payment Scheme.

Our deepest sympathies are with those who have experienced harm following vaccination and with their families. Ministers recognise that concerns have been raised with the Vaccine Damage Payment Scheme (VDPS) and continue to consider potential reforms to the scheme.In parallel, the Department has been working with the NHS Business Services Authority (NHS BSA), the administrators of the VDPS, to process claims at a faster rate. The time it takes to process a claim depends on the complexity of the case and the length of time healthcare providers take to supply the requested medical records. The NHS BSA is engaging with healthcare providers to improve the return rate of these records, which is essential to assessing claims, including though submitting subject access requests.Information on COVID-19 claims to the VDPS is published on a quarterly basis by the NHS BSA. Further information is available at the following link:https://opendata.nhsbsa.net/dataset/vdps-covid-19

What steps he is taking to help address Creon shortages in the NHS.

The Department is aware of ongoing intermittent supply issues with pancreatic enzyme replacement therapy (PERT), including Creon capsules. Supplies of Creon and other licensed alternatives have improved in the past year, and specialist importers have sourced unlicensed stock to assist in covering the remaining gap in the market. We continue to work closely with the manufacturers to resolve the issues as soon as possible and to ensure patients have continuous access to medicines.We have widely disseminated comprehensive guidance to healthcare professionals about these supply issues, which provide advice on how to manage patients whilst there is disruption to supply. This includes serious shortage protocols to limit prescriptions to one month’s supply to ensure equitable distribution of available supplies and that Creon remains available for those patients who need it. The Department has issued additional management advice to healthcare professionals which directs clinicians to consider the unlicensed imports when licensed stock is unavailable and includes actions for integrated care boards to have local mitigation plans in place and implemented to ensure that no patient is left without PERT.The Department also routinely engages with the affected patient advocacy groups and charities, clinicians, and other relevant stakeholders to ensure they are kept informed on the latest supply picture and any communications issued.

What assessment has he made of the potential implications for his policies of regional variation in access to cognitive behavioural therapy for insomnia (CBTi) across England.

No such assessment has been made. It is for local integrated care boards to decide whether treatments such as cognitive behavioural therapy for insomnia should be offered to their local populations as a treatment for insomnia.NHS Talking Therapies for anxiety and depression offer low-intensity therapy which may include interventions around sleep hygiene. Individuals who are experiencing symptoms of anxiety and/or depression can be referred by their general practitioner, or can self-refer, to NHS Talking Therapies. People can also access helpful resources on sleep problems on the Every Mind Matters website at the following link:https://www.nhs.uk/every-mind-matters/mental-health-issues/sleep/

If he will make an assessment of the potential merits of providing NHS provision of scleral contact lenses for patients with complex corneal conditions.

Scleral contact lenses can be funded by the National Health Service for hospital eye service patients if there is a clinical need.

What assessment his Department has made of the potential impact of furniture poverty on health outcomes.

The links between material deprivation and poorer mental and physical health are well recognised. As highlighted by the campaign ‘End Furniture Poverty’, furniture can be one of the most expensive items people can purchase, and living without essential items can have an impact on health.We know everyday life poses greater health risks to the most disadvantaged in society, and that the current model of healthcare works least well for those who already experience disadvantage and are far more likely to have complex needs. This is why the 10-Year Health Plan for the National Health Service in England sets out a reimagined service designed to tackle inequalities in both access and outcomes.The Department of Health and Social Care is also working with the Ministry of Housing, Communities and Local Government on housing quality and homelessness issues, including the new Decent Homes Standard and implementation of Awaab’s Law to improve the quality of rented homes.The Ministry of Housing, Communities and Local Government has invested in the Household Support Fund to enable local authorities in England to provide discretionary support to vulnerable households in the most need with the cost of essentials. People in need may be able to get help for essential furniture from their local council through the Household Support Fund and other services available locally.